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Abstract 
 
Extra-intestinal pathogenic E. coli (ExPEC) have a complex phylogeny, broad virulence 
factor (VF) armament and significant genomic plasticity, and are associated with a spectrum 
of host infective syndromes ranging from simple urinary tract infection to life-threatening 
bacteraemia. Their importance as pathogens has come to the fore in recent years, particularly 
in the context of the global emergence of hyper-virulent and antibiotic resistant strains. 
Despite this, the mechanisms underlying ExPEC transmission dynamics and clonal selection 
remain poorly understood. Large-scale epidemiological and clinical studies are urgently 
required to ascertain the mechanisms underlying these processes to enable the development of 
novel evidence-based preventative and therapeutic strategies. In the current review, we 
provide a concise summary of the methods utilised for ExPEC phylogenetic genetic 
delineation before exploring in detail the associations between ExPEC VFs and site-specific 
disease. We then consider the role of ExPEC as an intestinal colonist before outlining known 
associations between ExPEC clonal variation, specific disease syndromes and antibiotic 
resistance. 
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1. Introduction 
   
Escherichia coli is a genetically diverse species comprising non-pathogenic gut commensals 
and strains responsible for intestinal and extra-intestinal disease. While awareness amongst 
healthcare professionals and the public relating to E. coli strains associated with intestinal 
disease, e.g. enterohaemorrhagic E. coli (serogroup O157:H7), is high, the same has not 
always been true for strains associated with extra-intestinal disease (1). In the context of 
rapidly increasing multidrug-resistance worldwide and a diminishingly effective antimicrobial 
arsenal to tackle resistant strains, extra-intestinal E. coli infections are now a serious 
international public health concern associated with a significant economic impact. 
Consequently, there is an increasing awareness of the importance of extra-intestinal E. coli 
amongst both healthcare professionals and the general public alike (2,3). 
 
Historically, extra-intestinal E. coli isolates were separated into groups determined by 
disease-association, including uropathogenic E. coli (UPEC), neonatal meningitis-associated 
E. coli (NMEC), and sepsis-causing E. coli (SEPEC). These terms were subsequently deemed 
out-dated following the observation that E. coli isolates assigned to specific groups were 
capable of causing infection at multiple anatomical sites. In 2000, Russo and Johnson 
suggested the term extra-intestinal pathogenic E. coli (ExPEC) as an alternative descriptor for 
all non-commensal E. coli isolates capable of causing extra-intestinal disease (4). Unlike 
commensal E. coli, ExPEC have the ability to cause disease once outside the host gut 
reservoir due to the possession of pathogenic virulence factors.  From a molecular viewpoint, 
Peirano et al. (5) defined ExPEC as isolates containing at least two of the following virulence 
factors (VFs) within their genome: papA and/or papC, sfa/foc, afa/draBC, kpsM II and iutA 
(see table 1). 
 
ExPEC are most frequently implicated as urinary pathogens and are isolated as the infective 
agent in up to 90% of both simple community-acquired urinary tract infections (UTIs) and 
pyelonephritis cases. Other infections of the urinary tract, including prostatitis and catheter-
associated UTIs, are also frequently caused by ExPEC (6–8). ExPEC are frequently 
implicated in infections originating from abdominal and pelvic sources including, but not 
limited to, biliary infections, infective peritonitis, and pelvic inflammatory disease (9,10). 
Less frequently, they are associated with skin and soft tissue infections, neonatal meningitis 
and hospital-acquired pneumonia (11,12). Haematogenous invasion of ExPEC from the initial 
infective focus results in the sepsis syndrome which, in the absence of timely management, 
may result in death.  
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Following a brief overview of the methods used for ExPEC phylogenetic delineation, the 
current review will consider the role of ExPEC as a potential intestinal commensal and detail 
the associations between ExPEC strains, their virulence factor profiles, and host disease.  
 
2. ExPEC Lineage Determination; A Brief History 
 
Methodologies used to define and understand ExPEC lineages and E. coli phylogeny are 
numerous and have evolved in parallel with the availability of new technologies (see table 2). 
In-depth analyses are available elsewhere (13,14). Briefly, in the early 1970s, O antigen-
based serotyping, followed later by the addition of H and K antigen serotyping, was first 
utilised to delineate E. coli isolates from humans and other animals and allowed the 
identification of some of the E. coli strains we now refer to as ExPEC (15,16). In 1984, the 
pioneering work of Ochman and Selander led to the establishment of the E. coli reference 
strain collection (ECOR) comprising 72 isolates from human and other mammalian hosts 
(17). Multi-locus enzyme electrophoresis (MLEE) separated the isolates into five key 
phylogenetic groups (phylogroups), namely A, B1, B2, D and E. The distribution of ExPEC 
isolates within these phylogroups will be discussed in detail later, however they are mainly 
limited to groups B2 and D (see figure 1).  
 
In 2000, a triplex polymerase chain reaction (PCR)-based method was devised by Clermont et 
al. and enabled rapid E. coli phylogroup assignment (18). This methodology was much faster 
than MLEE, was simple and inexpensive, and allowed E. coli isolates to be separated into 
four main phylogroups (A, B1, B2, D). An updated multiplex PCR method was more recently 
devised by Doumith et al. (19). An independent study by Turrientes et al. subsequently 
compared both methods against a multi-locus sequence typing standard and demonstrated 
superiority of Doumith’s method with regards to accuracy of phylogroup assignment (20).  
 
Since 2000, the understanding of E. coli phylogeny has improved significantly. Eight E. coli 
phylogroups are currently recognised (A, B1, B2, D, E, F, G, and Clade 1) and a new PCR 
approach enables isolates to be assigned to one of these phylogroups (21).   
 
As DNA sequencing methods became more widely available, they superseded MLEE as the 
preferred technologies for phylogenetic analysis given their superior discriminative ability. 
Multi-locus Sequence Typing (MLST) involves sequencing of selected (often seven) bacterial 
housekeeping genes and, due to its standardised approach and greater resolution as compared 
with ‘phylogrouping’, has allowed more detailed analysis of ExPEC lineages (22,23). It 
separates the isolates into distinct sequence types (STs), which are defined as isolates with 
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identical allelic profiles, and into broader clonal complexes (CCs), which are defined as a 
group of at least three STs each differing from the others by no more than 1 of 7 alleles (24). 
Of the three MLST schemes available for E. coli, the Achtman scheme 
(http://mlst.warwick.ac.uk/mlst/dbs/Ecoli) is most commonly used (14). E. coli sequence type 
(ST) data presented in the current review are derived from the Achtman scheme unless 
otherwise stated. 
 
Although MLST is the preferred method for determining phylogenetic relationships in 
ExPEC, the discriminatory power of this technique is limited. Isolates belonging to the same 
ST can be genetically distinct and may be associated with variable pathotypic behaviours. In 
2012, Weissman et al. (25) described a new method, CH typing, which derives its name from 
fumC and fimH gene analysis. They demonstrated that this approach was able not only to 
predict the respective MLST-based profile with up to 95% accuracy, but that it also enabled 
large STs to be split into a number of smaller clonal sub-groups (25). Although CH typing 
will not replace MLST as a tool for phylogenetic studies, there are clear advantages of this 
technique, particularly relating to delineation of clones within STs and reduced costs when 
performing preliminary evaluations on larger clinical specimen collections (25,26).  
 
Ultimately, techniques such as pulsed-field gel electrophoresis (PFGE) and whole genome 
sequencing (WGS) provide the greatest resolution for the purposes of ExPEC phylogenetic 
analysis, such as may be needed for outbreak investigation. Although internationally-
standardised approaches, e.g. PulseNet (hosted by the Centre for Disease Control and 
Prevention), do allow for cross comparison of bacterial isolate PFGE results, the nature of any 
observed banding differences usually remains undefined. As a consequence of these factors, 
and as a result of the work-intensive nature of this method, PFGE is fast becoming an out-
dated method. By contrast, WGS offers definitive and semi-quantitative comparison between 
isolates, e.g. through comparative single nucleotide polymorphism (SNPs) studies. As the 
cost of WGS falls it is likely to be used increasingly for surveillance and routinely in clinical 
practice. However, for reasons relating to standardisation, the ST nomenclature derived from 
well-established MLST schemes seems likely to be retained, even if the PCR-based 
methodologies themselves are replaced and ST data are, in future, largely derived from whole 
genome analysis (14,27).  
 
3. ExPEC Virulence Factors  
 
Virulence factors (VFs) associated with ExPEC pathogenicity are numerous and broad in 
scope, ranging from those associated with colonisation and bacterial fitness, to those that are 
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more traditionally associated with the term virulence, e.g VFs associated with ExPEC host 
invasion. ExPEC VFs are encoded on the bacterial chromosome, where they are usually 
located within pathogenicity islands (PAIs), or on plasmids, and are separated into five main 
groups including: 1. adhesins; 2. toxins; 3. iron acquisition systems; 4. capsule production 
and; 5. protectins and invasins (table 1). Current evidence suggests that no single VF renders 
an ExPEC isolate capable of causing site-specific disease. Instead, site-specific ExPEC 
pathogenicity is likely related to the timely expression of a whole complement of VF genes. 
An ever-expanding body of evidence, derived mainly from epidemiological and in vitro 
studies, continues to explore the associations between particular ExPEC VFs and site-specific 
disease.  
 
3.1 Urinary Tract Infection-associated VFs 
 
UTI-associated ExPEC originate mainly from the host’s own faecal reservoir. Following 
urethral colonisation, ExPEC migrate proximally through the urinary tract to reach the 
bladder and kidneys where tissue invasion results in the clinical syndromes of cystitis and 
pyelonephritis, respectively (28,29).  
 
Proteins expressed on the external surface of ExPEC ensure successful urinary tract 
colonisation by binding uroepithelial cells. Type 1 fimbriae, assembled by the chaperon-usher 
secretion pathway, bind to uroepithelial-associated α-D-mannosylated proteins, e.g. 
uroplakins, via the distally-located fimbrial adhesin H (FimH) and represent a key mechanism 
underlying ExPEC urothelial adhesion (30). In vitro studies have demonstrated that 
conformational changes in the FimH adhesin, and the formation of catch bonds, occur as 
consequence of rising shear stress and result in increased tissue binding affinity (31,32). 
Although these are in vitro findings, they provide insight into the potential mechanisms that 
may facilitate continued colonisation in the presence of variable hydrostatic forces resulting 
from urinary flow observed within the urinary tract (30). Other VFs associated with 
uroepithelial adhesion include Dr binding adhesion (33), S fimbriae/F1C fimbriae (30,33) and 
P fimbriae (34).  
 
An array of VFs allows ExPEC to acquire ferric iron (Fe3+), which is required for optimal 
growth and continued persistence within the urinary tract. Siderophores including 
yersiniabactin, salmochelin and aerobactin enable ExPEC to internalise and utilise distantly 
scavenged Fe3+ for growth (35). Many ExPEC also carry genes encoding haem receptors, 
which enable direct haemin uptake, while others produce toxins including α-haemolysin, 
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which cause host uroepithelial injury, cell lysis, and the subsequent release of intra-cellular 
micronutrients (36–38).  
 
ExPEC are able to subvert the host immune response within the urinary tract through the 
production of conjugal transfer surface exclusion protein (TraT), an outer membrane protein 
associated with serum resistance (39). Furthermore, following uroepithelial cell invasion, 
ExPEC form intracellular bacterial communities (IBCs) that exhibit biofilm-like properties, 
protect bacteria from the host immune response, and are postulated to play a role in chronic 
infection and re-infection (40,41).  
 
Studies in humans provide insight into the likely importance of known ExPEC virulence 
factors and their association with UTI syndromes. While some VF-encoding genes are evenly 
distributed amongst UTI-associated ExPEC, others have a skewed distribution, favouring 
isolates associated with particular UTI syndromes. Presence of the pap operon, encoding P 
fimbriae, for example, has been associated with isolates obtained from patients with 
pyelonephritis (42). A recent study by Firoozeh et al. (43) compared the prevalence of VF-
encoding genes in 150 ExPEC isolates associated with UTI and demonstrated that pap, traT, 
aer and hly were more prevalent amongst patients with pyelonephritis compared with those 
suffering from cystitis. While these associations must be interpreted with caution, they do 
provide evidence to support the theory that VF profiles are likely to be associated with the 
propensity of ExPEC to cause site-specific disease within the urinary tract.  
 
3.2 Neonatal Meningitis-Associated VFs.  
 
ExPEC-related neonatal meningitis is associated with mortality rates approaching 40% and, in 
survivors, up to 50% develop significant neurological sequelae including seizures, 
hydrocephalus, encephalopathy and neurodevelopmental delay (44–46). The definitive 
mechanisms relating to blood brain barrier (BBB) invasion by ExPEC have yet to be 
completely elucidated, however the evidence base exploring these mechanisms comprising 
laboratory, animal and human studies continues to grow. 
 
High-level bacteraemia precedes the development of ExPEC neonatal meningitis (47,48). VFs 
that contribute to the ability of ExPEC to maintain high-level bacteraemia include those that 
allow it subvert the host immune response, e.g. the anti-phagocytic external capsule and 
serum-resistance-associated outer membrane protein A (OmpA) (49,50). As well as 
penetrating the BBB via transcellular and paracellular mechanisms, meningitis-associated 
pathogens may also be carried across the BBB as intracellular residents within phagocytes. 
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ExPEC VFs associated with BBB invasion include invasion of brain endothelium (ibe) 
proteins, OmpA, FimH, the bacterial capsule, and cytotoxic necrotising factor 1 (CNF1) 
(48,50). The molecular mechanisms underlying BBB invasion and the involvement of these 
VFs is discussed in detail elsewhere (12,50,51).   
 
3.3 VFs Associated with Bacteraemia and Gut Translocation 
 
The VF profiles of ExPEC strains from bacteraemia are highly variable. Iron-acquisition 
systems are essential for bacteraemia strains and include aerobactin and yersiniabactin 
siderophores, iron uptake systems, e.g. IroN and SitA systems, and ChuA haemin receptors 
(52). Serum resistance mechanisms, which subvert complement-mediated killing, are also 
essential in bacteraemia ExPEC strains and include capsular components, lipopolysaccharide, 
and genes encoding proteins involved in serum resistance, e.g. iss and traT (52,53).  
 
In vitro studies suggest that the ability of ExPEC to translocate across the intestinal mucosa is 
strain-specific and related to localised inflammatory and metabolic stressors (54). A 
collection of small association studies have attempted to establish the role of particular VFs 
associated with intestinal translocation and have all demonstrated that a collection, as 
opposed to individual VFs, are likely to be related to these events (55–57). In a recent study, 
Krawczyk et al. (57) assessed VF profiles of ExPEC bacteraemia isolates derived from bowel 
translocation events in patients with haematological malignancy and concluded that the co-
occurrence of multiple virulence genes was associated with an increased likelihood of 
intestinal translocation events.  
 
 
4. ExPEC as an Intestinal Colonist 
 
 
Over the last decade, a number of authors have sought to establish the prevalence of E. coli 
with ExPEC potential colonising the gut by performing microbiological screening studies on 
the stool of healthy individuals that delineate resident E. coli strains based on their 
phylogroup (58–63). Results of these studies have demonstrated that 11-48% of healthy 
individuals are colonised with E. coli belonging to phylogroup B2, which is traditionally 
associated with virulence and ExPEC infections. The observed variation in the prevalence of 
asymptomatic gut carriage of strains belonging to phylogroup B2 is multifactorial and likely 
represents differences in geographical, population, and sampling-related factors.  
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Although it is clear that colonisation with E. coli isolates from phylogroup B2 is common, 
what is less clear is the associated virulence potential of phylogroup B2 isolates carried by 
asymptomatic individuals as determined by VF profile analysis. A recent review by Erjavec et 
al. (64) systematically assessed published studies that performed genomic VF profiling on gut 
colonising E. coli isolates in asymptomatic individuals. Their analysis demonstrated that, of 
26 well-established ExPEC-associated VFs, molecular screening of only 7 (Afa, CNF-1, Fim, 
HlyA, Iuc, P fimbriae, and S/F1C fimbriae) was performed in over half of the 21 studies 
identified. This review highlights the lack of knowledge in this area and future studies are 
required to further our understanding of the full complement of VFs carried by E. coli strains 
belonging to all phylogroups, but particularly to those belonging to phylogroups B2 and D. 
Despite the aforementioned limitations, the analysis by Erjavec et al. demonstrated that 
ExPEC-associated VF genes were carried by ≥10% of colonising E. coli strains. This data 
supports the theory that, in a large proportion of healthy individuals, the intestine is a 
potential reservoir for ExPEC. 
 
Following the observation that a number of ExPEC VFs were associated with intestinal 
persistence (65–67), including genes encoding P fimbriae, type 1 fimbriae, haemolysin and 
aerobactin, Nowrouzian et al. (65) postulated that these factors may first and foremost be 
fitness-associated, with uropathogenicity being a side-effect. A subsequent study by the same 
authors assessed the changes in the commensal faecal E. coli population in 70 infants over the 
period of a year (59); E. coli isolates belonging to phylogroup B2 were far more likely to be 
resident as opposed to transient faecal strains over the study period (p=0.004), while isolates 
belonging to phylogroups A, B1 or D were not. Interestingly, the prospect of undiscovered 
adherence-related factors was postulated following results of multivariate logistic regression 
analysis on the same dataset, which demonstrated that phylogroup B2 faecal E. coli residency 
was independent of all identified VFs (59).  
 
The evidence discussed provides insight into the proportion of individuals carrying 
potentially pathogenic E. coli within their normal intestinal flora. However, despite 
harbouring ExPEC with varied VF profiles, infection does not develop in many individuals. 
This finding highlights the importance of non-pathogen-related factors, e.g. host factors, and 
their associations with susceptibility to and severity of infection. In relation to UTI, for 
example, host factors associated with an increased risk of infection include being female 
(shorter urethral length), anatomical abnormalities of the urinary tract, a pre-existing 
diagnosis of diabetes mellitus, and the presence of an indwelling urinary catheter (7,39,68). 
Advanced age has also been associated with increasing severity of infection (69) and, in a 
recent retrospective study by Wester et al., poorer outcomes were associated with age ≥65 
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years (p=0.042) and the presence of ≥1 medical co-morbidity (p=0.003) in a cohort of 212 
patients admitted from the community with ExPEC bacteraemia secondary to UTI, respiratory 
tract infection, gastro-intestinal infection or infection of unknown origin (70).  
 
Colonising E. coli lacking ExPEC-associated VFs, hypothetically belonging to any 
phylogroup, may become potentially virulent organisms as a result of horizontal transfer of 
virulence genes from other Enterobacteriaceae (64). Furthermore, E. coli strains are 
frequently shared among family members, including pets (71). These abilities make for a 
dynamic ecology and have the potential to result in the widespread distribution of potentially 
pathogenic ExPEC strains amongst a broad population. Large pan-genomic studies are 
warranted to assess the distribution and prevalence of virulence genes across diverse E. coli 
STs and to understand this dynamic process better.  
 
5. ExPEC Clonal Variation and Associations with Disease and Antibiotic Resistance 
 
5.1 Clonal Variation  
 
MLEE analysis demonstrates that the majority of ExPEC strains from immunocompetent 
individuals belong to phylogroup B2 or, less commonly, phylogroup D. In contrast, 
commensal E. coli strains and those associated with enteric disease are generally derived from 
phylogroups A/B1 or A/B1/D, respectively (72). However, these delineations are not absolute 
and isolates from non-B2/D groups have been associated with extra-intestinal infection. More 
recently, MLST analysis of ExPEC strains has provided greater resolution within these 
phylogroups and has revealed associations between specific ExPEC STs and host disease 
syndromes.  
 
Data from international studies reporting the distribution of ExPEC STs based on the 
Achtman MLST scheme isolated from individuals with ExPEC infection syndromes 
demonstrate the extent of ExPEC diversity. However, the world-wide predominance of STs 
69, 73, 95 and 131 is clearly evident (26,73,74). In a study based in Minnesota, USA, 
Banerjee et al. identified 47 ExPEC STs from 299 community and healthcare-associated 
isolates (90% of isolates from urine), the most common being ST131 (27%), ST95 (11%), 
ST73 (8%), ST127 (6%) and ST69 (5%) (26). In a further American study including only 
patients from one hospital in San Francisco, 246 consecutive ExPEC bacteraemia isolates 
were analysed over a 3-year period. ST12 CC, ST69, ST73 CC, ST95 and ST131 accounted 
for 66% of isolates (74). Data from the UK also demonstrate similar findings. For example, a 
recent study by Horner et al. revealed that ExPEC STs 69, 73, 95 and 131 accounted for 55% 
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of 770 ExPEC bacteraemia isolates studied in a surveillance programme in northern England 
over 2 years (75). A further study by Gibreel et al. carried out in the north west of England, 
UK, demonstrated that among 300 ExPEC isolates responsible for UTI, the most common 
STs were ST73 (16.6%), ST131 (12.3%), ST69 (9%), ST95 (6.3%), ST10 (4.3%) and ST127 
(3.6%)(76).  
 
5.2 Disease Associations 
 
Studies outlining associations between ExPEC STs and specific disease syndromes report 
variable results. In a study comparing men with ExPEC pyelonephritis (n=101) versus cystitis 
(n=153), prevalence of ST131 was significantly higher in the pyelonephritis group (36% vs. 
8% p<0.001) (77). A further study associated the ST131 clonal subgroup, ST131 H30 (as 
determined by CH typing), with the propensity to cause persistent or recurrent UTI, and 
sepsis (78). However, in a further study by Chung et al., which assessed clinical outcomes in 
122 patients with extended-spectrum beta-lactamase (ESBL) E. coli bacteraemia, 14- and 28-
day mortality rates were similar in patients with infections caused by ST131 versus non-
ST131 ExPEC STs (79). Other authors have also associated ExPEC STs 127 and 73 with 
pyelonephritis (25). From the non-infectious viewpoint, E. coli belonging to phylogroup B2 
have recently been associated with inflammatory bowel disease in a systematic review and 
meta-analysis by Petersen et al. (80). Although these findings are interesting, further studies 
are required to understand whether IBD is a consequence of, or a cause of, intestinal 
colonisation with E. coli belonging to phylogroup B2. 
 
Following on from their early work, which demonstrated an association with phylogroup B2  
E. coli isolates and urosepsis (81), Jaureguy et al. published a comprehensive study assessing 
associations between 161 consecutively collected E. coli bacteraemia isolates, infective 
source, and clinical outcomes (73). Eighty-seven STs were identified, using the Pasteur 
MLST scheme rather than the Achtman scheme, and categorised into 19 CCs, 11 of which 
comprised ≥5 isolates. There was a significant association between CC1 and CC4 (the two 
major clones identified from phylogroup B2) and urinary tract infection as a source of 
bacteraemia when compared with other B2 genotypes (UTI-associated bacteraemia accounted 
for 12/17 and 11/17 of isolates belonging to CC1 [p=0.017] and CC4 [p=0.041], 
respectively). Conversely, a further phylogroup B2 clone, CC32, was associated with non-
urinary tract source of bacteraemia (p=0.023). No association between CCs and infection 
severity or clinical outcome was demonstrated. This study confirmed that clonal groups rather 
than whole phylogroups were more appropriate phylogenetic delineators to be utilised for the 
purpose of association studies.  
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Although MLST allows greater discrimination than MLEE, strains within specific STs may 
possess varied genotypes affecting pathogenicity. For example, ExPEC ST73 includes two 
probiotic E. coli strains, Nissle 1917 and the asymptomatic bacteriuria (ABU) strain 83972, as 
well as the highly virulent uropathogenic CFT073 strain. Vejborg et al. utilised a comparative 
genomic hybridisation (CGH) microarray analysis to compare the genomes of Nissle 1917, 
ABU 83972 and CFT073 E. coli strains. (82). Their results revealed only minor genetic 
differences between the three strains and suggested that they likely originated from a common 
ancestor. Almost all known CFT0730-associated VFs were present in Nissle 1917 and ABU 
83972 and, interestingly, ABU 83972 contained additional PAI-associated regions when 
compared with CFT0730. The authors suggested that the observed differences in 
pathogenicity between the three strains seemed likely to be a consequence of differential gene 
expression. However, they also noted that genetic mutations (deletions or point mutations) 
were present in both Nissle 1917 and ABU 83972 that may have directly altered 
pathogenicity by altering expression of type 1, P and F1C fimbriae as well as PAIs associated 
with haemolysis and haemagglutination. These findings highlight the potential pitfalls of 
epidemiological research solely assessing the presence of VF genes and emphasise the 
importance of considering phenotypic bacterial properties. A spectrum of clinical disease 
syndromes, ranging from neonatal meningitis to urinary sepsis, has also been observed for 
ExPEC strains belonging to ST95 (25,82,83). 
 
Pathotypic variations observed within members of the same ST demonstrate the potential 
limitations of MLST, particularly when it is used in the context of clinical association studies. 
WGS and PFGE provide greater phylogenetic resolution and are both valuable in the context 
of surveillance and outbreak analysis. PFGE is still widely utilised and international 
standardisation does allow for profile cross-comparison. However, as previously mentioned, 
this method is particularly labour-intensive and the cause of any identified banding 
differences cannot be easily established. Conversely, WGS provides for full standardisation 
and easy comparison of results and, if necessary, MLST profiles can be determined 
retrospectively. As a consequence of these features, and given that in the future the 
technology will become increasingly automated, WGS will likely become widely used. As a 
consequence, the use of PFGE will in the main become redundant.  
 
Although WGS provides superior phylogenetic resolution, this technology is not yet widely 
utilised and is currently associated with significant cost. As a consequence, in the setting of 
an outbreak where phylogenetic information may significantly alter the subsequent 
management strategy, the delivery of real-time information using WGS is still currently 
limited in most hospitals. These observations led Weissman et al. (25) to develop ‘CH 
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typing’, a two-locus typing method, which utilises a 489-bp internal fragment of the type 1 
fimbria adhesin gene, fimH, and a 169-bp internal fragment of the MLST locus, fumC. When 
evaluated on ExPEC isolates, CH typing predicted STs with 95% accuracy, while providing 
greater phylogenetic resolution than MLST. Of particular importance, CH typing enabled 
dominant ExPEC STs, accounting for large proportions of isolates e.g. ST131, ST73, ST127, 
to be divided into smaller clonal groups. The authors commented that, although CH typing 
will not replace traditional MLST or WGS/PFGE for detailed phylogenetic studies, it may 
have value as a rapid screening test in the setting of an outbreak, or where sub-ST clonal 
diversity may be important, e.g. in determining antibiotic resistance patterns associated with 
ST-specific clones, where time and financial constraints limit immediate use of 
methodologies with higher resolving power (25).  
 
 
5.3 Antibiotic Resistance Associations 
 
The importance of rapid, high-throughput typing methods becomes apparent on considering 
the variation in antimicrobial resistance profiles observed between ExPEC STs. In the UK, 
ExPEC ST131 isolates now account for the majority of multidrug-resistant ExPEC strains, 
and, as well as being associated with fluoroquinolone and aminoglycoside resistance, often 
carry ESBLs, particularly of the CTX-M-type (76,84). By contrast, ExPEC STs 69, 73 and 95 
are less often associated with multi-resistance and generally remain susceptible to extended-
spectrum cephalosporins, although the reasons for this are poorly understood. From the 
clinical viewpoint, establishing the antimicrobial susceptibility profile rapidly in patients with 
ExPEC infections is paramount and will guide subsequent antimicrobial therapy. With this in 
mind, Doumith et al. (84) recently devised a novel multiplex PCR technique that enables the 
rapid identification of ExPEC STs 69, 73, 95 and 131. Results of validation studies against 
MLST demonstrated that the new multiplex PCR assay was 100% sensitive and 99.5% 
specific. It is predicted that technologies such as this will be highly valuable where rapid 
results are required locally, e.g. in the hospital clinical microbiology setting.  
 
ExPEC ST131 was first reported in 2008 and is now considered a pathogen of global 
importance (85). Recent molecular epidemiological studies have revealed a number of ST131 
clonal subgroups associated with variable antimicrobial resistance patterns, the most 
prevalent being ST131 clonal subgroup H30  (contains the H30 variant of fimH) (86–88). A 
number of ST131 H30 subgroups, mainly H30-R (encodes fluoroquinolone resistance), 
H30(non-R) and H30-Rx (encodes fluoroquinolone resistance and produces CTX-M-15 
ESBL), have subsequently evolved through a process of clonal selection from a common 
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ST131 H30 ancestor (see figure 2) (88–90). The rapid emergence of multidrug-resistant 
ST131 and its associated subclones has significant clinical consequences, particularly when 
considering appropriate empirical antimicrobial regimens. CH typing is likely to be beneficial 
in this setting as it allows for the rapid identification of the ST131 H30 subclone and may be 
used as an initial high-throughput screening test in the context of an outbreak or to guide 
initial empirical antimicrobial choice (86,90). An in-depth analysis relating to ExPEC ST131 
and its associated clonal subgroups is beyond the scope of this review but is available 
elsewhere in two comprehensive reviews by Banerjee and Johnson (90) and Mathers et al. 
(85).  
 
6. Conclusions 
 
E. coli is a genetically diverse species with a complex phylogeny, broad VF armament and 
significant genomic plasticity. In recent years, the importance of ExPEC as pathogens capable 
of causing a spectrum of host infective syndromes has come to the fore, particularly in the 
context of the emergence of multidrug-resistance. Particular STs of ExPEC isolates, e.g.  
ST131, ST73 and ST127, have emerged globally as the predominant strains responsible for 
disease, however the underlying reasons for their success are yet to be fully elucidated. 
Pathogen-related factors may include increased bacterial fitness resulting in enhanced 
colonisation ability, increased virulence, and selection pressure resulting from widespread use 
of broad-spectrum antimicrobial agents. Meanwhile environmental factors including sub-
standard infection-control practices and increased international travel are also of likely 
significance. 
 
Individual VFs or VF profiles have been associated with site-specific infections and broadly 
belong to one of five groups including adhesins, toxins, iron acquisition systems, capsular 
components and protectins/invasins. Studies to date tend to assess the virulence of an ExPEC 
isolate based on the detection of chromosomally-encoded VFs. However throughout this 
review, evidence has been presented to demonstrate the variable clinical syndromes that may 
result from infection with genetically similar strains. Hence, although genetic studies are 
valuable in the context of disease association studies, the potential for significant phenotypic 
variation must not be ignored.  
 
Host factors and susceptibility to ExPEC infections are of significant importance and must be 
accounted for when performing genetic association studies. In the context of a growing 
evidence base relating to a high proportion of asymptomatic intestinal carriage of potentially 
pathogenic E. coli, the consideration of host factors becomes increasingly important. 
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However to date, the true extent of asymptomatic ExPEC carriage is yet to be fully 
elucidated. Large-scale pan-genomic carriage studies, ideally of prospective design, are now 
required to ascertain the true extent of the intestinal ExPEC reservoir and to understand better 
the complex dynamics of carriage.  
 
Novel strategies to prevent, rapidly diagnose and treat ExPEC infections are needed, 
particularly in the context of the recently observed clonal expansion of specific hyper-virulent 
and antibiotic-resistant strains. Large-scale epidemiological and clinical studies are required 
to ascertain the mechanisms underlying transmission dynamics and clonal selection, and to 
allow for an evidence base to be established from which new preventative or therapeutic 
strategies could be devised. Potential strategies might relate to the deployment of targeted 
infection control measures or the development of targeted national/international antimicrobial 
prescribing policies. Detailed molecular studies, particularly relating to the mechanisms 
underlying invasive disease and asymptomatic intestinal carriage, must also be performed to 
guide the development of both preventative strategies, e.g. potential vaccine production, and 
new treatment strategies, e.g. therapeutic strategies targeting novel bacterial factors.  
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Table 1 – ExPEC Virulence Factors  
  
Virulence Factor Gene(s) Ref. 
Adhesins 
        Adhesion siderophore iha (91) 
        Dr-binding adhesins afa/draBC (91) 
        E. coli common pilus ecpA (92) 
        F1C fimbriae  foc gene cluster (93) 
        Heat-resistant haemagglutinin hra (91) 
        M fimbriae bmaE (94) 
        N-acetyl D-glucosamine-specific fimbriae gaf (95) 
        P fimbriae  papACEFG  (91,96) 
        S fimbriae sfa/sfaS (96) 
        Temperature sensitive haemagglutinin  (91) 
        Type 1 fimbriae fimH (91) 
Iron Acquisition Systems 
        Aerobactin receptor iutA (91) 
        Peri-plasmic iron binding protein SitA (95) 
        Salmochelin receptor iroN (91) 
        Siderophore receptor ireA (91) 
        Yersiniabactin receptor fyuA (91) 
Protectins and Invasins 
        Colicin V Cva (95) 
        Conjugal transfer surface exclusion protein  traT (95) 
        Group 3 capsule kpsMT II (91) 
        Increased serum survival iss (91,95) 
        Invasion of brain endothelium ibeA (97) 
        K1/K2/K5 group 2 capsule variants K1/K2/K5 genes (91) 
        kpsM II group 2 capsule kpsM II (91) 
        Outer membrane protease T ompT (91,95) 
Toxins 
       α-haemolysin hylD (91) 
        Cytolethal distending toxin cdtB (97) 
        Cytotoxic necrotising factor Cnf1 (48) 
        Enteroaggregative E. coli toxin astA (91) 
        Haemolysin A hylA (50) 
        Secreted autotransporter toxin sat (91) 
        Serine protease pic (91) 
        Vacuolating toxin vat (91) 
Others 
       β-glucoronidase uidA (97) 
        Colibactin synthesis Clb & clbB (97) 
        Uropathogenic-specific protein usp (91) 
        Flagellin variant H7 fliC (91) 
        Maltose and glucose-specific PTS transporter 
____subunit IICB 
MalX (95) 
        Pathogenicity island marker malX (91) 
        D-serine deaminase DsdA (95) 
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Table 2  - Strengths and Weaknesses of ExPEC Typing Methods. 
 
Typing Method Strengths Weaknesses 
Phenotypic   
 
Multi-locus enzyme 
electrophoresis 
(MLEE) 
 
• Majority of strains can be typed. 
• Easy to interpret results. 
 
 
• Provides poor 
phylogenetic resolution 
compared with newer 
techniques. 
Genetic   
 
Multiplex-PCR-based 
techniques  
 
• Allow for rapid determination of 
phylogroup or ST. 
• Potential application in clinical 
setting (e.g. in predicting likely 
antibiogram or as screening tool 
in the setting of an outbreak 
• Relatively low cost. 
 
 
• Only allow for 
detection of specific 
genomic targets as 
determined by primer 
mix. 
 
 
Pulse-field Gel 
Electrophoresis 
(PFGE) 
 
• Highly discriminative method 
with excellent phylogenetic 
resolution and epidemiological 
concordance. 
• Standardised systems available 
to aid in interpretation and 
cross-comparison with other 
isolates, e.g. Pulsenet. 
• Highly reproducible. 
 
• Labour-intensive, time-
consuming and 
technically demanding. 
• Results available in 
days. 
• Resolution limited 
when DNA fragments 
of similar size. 
• Although 
standardisation systems 
exist, an element of 
subjectivity remains. 
 
Multi-locus sequence 
typing (MLST) 
• Generated data highly portable 
compared with those produced 
by PFGE.  
• Internationally-standardised 
system that is highly 
reproducible. 
 
• Phylogenetic resolution 
is limited.  
• Expensive. 
 
Whole Genome 
Sequencing (WGS) 
 
• Provides the highest level of 
phylogenetic resolution and 
discriminatory power.  
• MLST can be determined from 
WGS data to allow for cross-
comparison. 
• Lends itself to being automated.  
 
  
 
• Currently expensive 
(although now 
probably cheaper than 
MLST) 
• Requires significant 
resources, particularly 
bioinformatics 
expertise following 
initial sequencing. 
• At present results and 
analysis are time 
consuming are 
therefore at present  
mainly used in research 
setting.  
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Figure 1 – Phylogeny of a selection of complete E. coli genome sequences based on whole 
genome alignment. Methodology utilised to derive phylogenetic tree outlined in detail 
elsewhere (61). Figure reproduced with kind permission from Leimbach et al. (61) and 
Spinger Science and Business Media. 
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Figure 2 - Schematic dendrogram of ST131 phylogeny reconstructed using whole-genome 
single nucleotide polymorphism analysis. Arrows indicate emergence of fimH30 allele, FQ 
resistance, and CTX-M-15 ESBL. Colors indicate resistance traits significantly associated 
with (although not confined to) specific lineages. FQ, fluoroquinolone; TMP-SMZ, 
trimethoprim-sulfamethoxazole; R, resistance. Figure and legend reproduced with kind 
permission from Banerjee and Johnson (90) and The American Society for Microbiology. 
 
 
 
  
